Key Points {#FPar1}
==========

With the increasing prevalence of obesity and associated co-morbidities, including impaired glucose tolerance and type 2 diabetes mellitus, novel treatment strategies are needed.SGLT2 inhibitor monotherapy does not provide sufficient weight loss for successful treatment of obesity.Co-administration of SGLT2 inhibitors together with agents that reduce food intake target complementary mechanisms and represent an effective weight loss therapy.

Introduction {#Sec1}
============

Obesity is a growing health issue that has reached pandemic proportions, and in the last 15 years the estimated prevalence has doubled. In 2016, 1.9 billion (about 40%) of the glo bal adult population were overweight or obese, and of these 650 million were obese according to the World Health Organization \[[@CR1]\]. Overweight and obesity, in particular, intra-abdominal adiposity, are associated with various cardiometabolic conditions including type 2 diabetes (T2D), dyslipidemia, hypertension, atherosclerotic cardiovascular disease, and heart failure \[[@CR2], [@CR3]\]. In addition, various musculoskeletal, respiratory, renal, gastrointestinal, and psychiatric complications are linked to obesity \[[@CR4], [@CR5]\]. As a consequence, there are major implications for the affected individual's quality of life and also for society, including healthcare costs.

Weight loss in obese subjects improves several of the associated health issues, for example, prediabetes, diabetes, hypertension, and dyslipidemia \[[@CR6]--[@CR8]\]. Bariatric surgery has to date been the most effective treatment, and it has demonstrated a reduction of risks for cardiovascular events, cancer, and premature death, and pre-existing T2D is often reversed to normoglycemia \[[@CR9]--[@CR11]\].

The cornerstone treatment for overweight and obesity is lifestyle modification, mainly a lower energy intake in combination with increased physical activity. Adjuvant pharmacotherapies typically have demonstrated modest efficacy, and this may partly be due to physiological counter-regulatory mechanisms. Combination pharmacotherapies may achieve greater bodyweight loss than monotherapies, via additive or synergistic effects, when the individual agents target different pathways \[[@CR12]\].

Selective sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin-independent mechanism for improving blood glucose levels and are approved for the treatment of T2D. They promote urinary glucose excretion by inhibiting glucose reabsorption from urine in the proximal tubule in the kidney (up to about 50%). The magnitude of the resulting glucosuria is proportional to the plasma glucose above the threshold \[[@CR13]\].

SGLT2 inhibitors (e.g., dapagliflozin, canagliflozin, and empagliflozin) and glucagon-like peptide-1 receptor agonists (GLP1-RAs; e.g., exenatide, liraglutide, and semaglutide) are both used for T2D treatment, but they also lead to bodyweight loss, largely accounted for by body fat reduction. Moreover, the glycemic as well as bodyweight effects are sustained over several years with these drug classes \[[@CR14]--[@CR16]\]. However, the magnitude of weight loss is modest both in T2D and in obesity without diabetes. For approved SGLT2 inhibitors there is on average some 1.5--2 kg weight loss (placebo-adjusted), for GLP1-RAs 2--4 kg, and for the combination 3--5 kg \[[@CR17]--[@CR23]\]. Thus, there is a need for more effective weight-loss therapies.

This article reviews current knowledge about weight loss with SGLT2 inhibitors in T2D subjects and obese subjects without T2D and provides future insight for using SGLT2 inhibitors alone or in combination therapy as treatment for obesity.

Clinical Effect of SGLT2 Inhibitors {#Sec2}
===================================

The efficacy and safety of SGLT2 inhibitors have been extensively investigated, especially in combination with metformin and/or other glucose-lowering drugs in T2D patients. In addition to glucose control, SGLT2 inhibitors have been shown to have beneficial effects on body weight, systolic blood pressure, and on the risks for major cardiovascular and renal events. In this section, we provide an overview of the clinical effects of SGLT2 inhibitors in patients with T2D and in obese individuals without diabetes.

Glycemic Control {#Sec3}
================

SGLT2 inhibitors have shown consistent reductions in HbA1c levels from baseline in patients with T2D at all time points. Meta-analyses show mean differences in HbA1c reductions versus placebo of − 1.4% to − 0.5% \[[@CR20], [@CR22], [@CR24]--[@CR27]\]; these reductions are similar to those of other glucose-lowering agents \[[@CR28]\]. These results are not surprising for a drug developed for the treatment of T2D. Clinical trials examining the effects of SGLT2 inhibitors in HbA1c in overweight or obese subjects without T2D are limited (Table [1](#Tab1){ref-type="table"}). In two studies of 12- and 24-week duration, SGLT2 inhibitors alone (canagliflozin and dapagliflozin, respectively) did not affect HbA1c levels compared to placebo in overweight and obese subjects \[[@CR29], [@CR30]\]. However, SGLT2 inhibitors in combination with a GLP1-RA significantly reduced HbA1c in obese subjects without diabetes, compared to placebo (Table [1](#Tab1){ref-type="table"}) \[[@CR30], [@CR31]\].Table 1Effects of SGLT2 inhibitors on body weight in obese individuals without type 2 diabetesReference, yearDuration (week)*N*Treatment armsBodyweight change from baseline\
(kg)Other effectsSGLT2 inhibitors Bays et al. 2014 \[[@CR29]\]12376Placebo\
Canagliflozin 50 mg\
Canagliflozin 100 mg\
Canagliflozin 300 mg− 1.1\
− 1.9\
− 2.8\
− 2.4↓ BMI, SBP\
↑ UGE/creatinine ratio, LDL-C/HDL-C, IWQOL-Lite total scores\
= TG, HDL-C, FPG, HbA1c, pulse rate Napolitano et al. 2014 \[[@CR82]\]830Placebo + diet (− 500 cal)\
Remogliflozin etaborate 250 mg + diet (− 500 cal)\
Sergliflozin etaborate 1,000 mg + diet (− 500 cal)− 5.1\
− 7.6\
− 6.1↓ Fat mass, fat free mass, leptin/adiponectin\
↑ UGE Ramirez-Rodriguez et al. 2018 \[[@CR23]\]1224Placebo\
Dapagliflozin 10 mg− 1.0\
− 3.0↓ FPG, uric acidSGLT2 inhibitors +GLP1-RA  Lundkvist et al. 2016 \[[@CR83]\]2450Placebo\
Dapagliflozin 10 mg + Exenatide 2 mg− 0.4\
− 4.5 ↓ VAT, SAT, TAT, HbA1c, 2-h PG, IFG, SBP\
↑ UGE\
= total lean tissue, liver fat, serum lipids Lundkvist et al. 2017 \[[@CR21]\]5250Dapagliflozin 10 mg + Exenatide 2 mg− 5.7SGLT2 inhibitors + phentermine Hollander et al. 2017 \[[@CR42]\]26335Placebo\
Canagliflozin 300 mg\
Phentermine 15 mg\
Canagliflozin + Phentermine 15 mg− 0.6\
− 1.9\
− 4.1\
− 7.3↓ SBP\
↑ Pulse rate (Phentermine, Canagliflozin + Phentermine)\
= plasma lipids*BMI* body mass index, *SBP* systolic blood pressure, *UGE* urinary glucose excretion, *LDL*-*C* low density lipoprotein-cholesterol, *HDL*-*C* high-density lipoprotein-cholesterol, *IWQOL* Impact of Weight on Quality of Life, *TG* triglycerides, *FPG* fasting plasma glucose, *VAT* visceral adipose tissue, *SAT* subcutaneous adipose tissue, *TAT* total adipose tissue, *2*-*h PG* 2-h post-OGTT plasma glucose, *IFG* impaired fasting glucose, ↓ reduction, ↑ increase, = no change

Meta-analysis shows that SGLT2 inhibitors significantly reduce fasting blood glucose values from − 2.0 to − 1.1 mmol/L \[[@CR26]\]. The glucose-lowering capacity of SGLT2 inhibitors is blood glucose-dependent \[[@CR32]\], which minimizes hypoglycemic events. The plasma glucose concentration is mainly determined by hormonal and neural factors (like insulin, glucagon, and catecholamines), which regulate endogenous production of glucose \[[@CR33]\]. SGLT2 inhibitors stimulate hepatic glucose production and also increase glucagon secretion, which promotes endogenous glucose production and restricts their glucose-lowering capacity \[[@CR34]\].

Effects on Body Weight and Adiposity {#Sec4}
====================================

SGLT2 inhibitors directly cause body weight loss via glucose excretion (calorie loss) in the kidneys. Inhibition of SGLT2 acts in a glucose-dependent manner and can result in the elimination of about 60--100 g of glucose per day in the urine. Weight loss with SGLT2 inhibitor therapy has been consistently observed in several studies in T2D, whether patients are taking SGLT2 inhibitors as monotherapy or in combination with additional glucose-lowering therapies (Table [2](#Tab2){ref-type="table"}). The results of network meta-analyses show reductions of body weight compared to placebo for all SGLT2 inhibitor treatments of about 1.5--2 kg \[[@CR26]--[@CR28], [@CR35]\] and these effects are dose-dependent \[[@CR36]\]. Clinical data up to 4 years show that bodyweight reduction with SGLT2 inhibitors is maintained \[[@CR37]--[@CR39]\]. However, SGLT2 inhibitors cause substantially less weight loss than expected from the energy excreted via glycosuria, because it elicits an adaptive increase in energy intake, including compensatory increases in appetite/caloric intake \[[@CR40]\]. Therefore, combining SGLT2 inhibitors with drugs acting via different mechanisms might be the most effective approach for major weight loss and address counter-regulatory mechanisms that maintain body weight \[[@CR41]\]. Recent studies evaluating the co-administration of SGLT2 inhibitors with other classes of drugs have shown promising results. For example, the DURATION-8 study demonstrated that mean bodyweight loss with the combination of exenatide (GLP1-RA, which suppresses appetite) once weekly and dapagliflozin (SGLT2 inhibitor) once daily in patients with T2D was greater than that with the monotherapies alone \[[@CR17]\].Table 2Effects on body weight in randomized clinical studies using SGLT2 inhibitors as monotherapy or combined with other type 2 diabetes therapyReferenceDuration to end point (week)*N*Study populationTreatment armsBodyweight change from baseline (kg)SGLT2 inhibitor Bailey et al. 2012 \[[@CR84]\]24282T2DPlacebo\
Dapagliflozin 1 mg\
Dapagliflozin 2.5 mg\
Dapagliflozin 5 mg− 1.0\
− 2.7^a^\
− 2.6^a^\
− 2.7^a^ Ferrannini et al. 2010 \[[@CR85]\]24485T2DPlacebo\
Dapagliflozin 2.5 mg\
Dapagliflozin 5 mg\
Dapagliflozin 10 mg− 2.2\
− 3.3\
− 2.8\
− 3.2 Ji et al. 2014 \[[@CR86]\]24326T2DPlacebo\
Dapagliflozin 5 mg\
Dapagliflozin 10 mg− 0.3\
− 1.6^a^\
− 2.6^a^ Kaku et al. 2014 \[[@CR87]\]24261T2DPlacebo\
Dapagliflozin 5 mg\
Dapagliflozin 10 mg− 0.8\
− 2.1^a^\
− 2.2^a^ Lambers Heerspink et al. 2013 \[[@CR58]\]1275T2DPlacebo\
Dapagliflozin 10 mg− 0.1\
− 2.4^a^SGLT2 inhibitor + metformin or sulfonylurea Bailey et al. 2010 \[[@CR88]\] 24 546T2DPlacebo + Metformin\
Dapagliflozin 2.5 mg\
Dapagliflozin 5 mg\
Dapagliflozin 10 mg− 0.9\
− 2.2^a^\
− 3.0^a^\
− 2.9^a^ Bailey et al. 2013 \[[@CR89]\]102546T2DPlacebo + Metformin\
Dapagliflozin 2.5 mg\
Dapagliflozin 5 mg\
Dapagliflozin 10 mg+ 1.4\
− 1.1^a^\
− 1.7^a^\
− 1.7^a^ Bolinder et al. 2012 \[[@CR90]\]24182T2DPlacebo + Metformin\
Dapagliflozin 10 mg− 0.9\
− 3.0^a^ Bolinder et al. 2014 \[[@CR37]\]102182T2DPlacebo + Metformin\
Dapagliflozin 10 mg− 2.1\
− 4.5^a^ Strojek et al. 2011 \[[@CR91]\]24597T2DPlacebo + Glimepiride\
Dapagliflozin 2.5 mg + Glimepiride\
Dapagliflozin 5 mg + Glimepiride\
Dapagliflozin 10 mg + Glimepiride− 0.7\
− 1.2\
− 1.6^a^\
− 2.3^a^ Strojek et al. 2015 \[[@CR92]\]48597T2DPlacebo + Glimepiride\
Dapagliflozin 2.5 mg + Glimepiride\
Dapagliflozin 5 mg + Glimepiride\
Dapagliflozin 10 mg + Glimepiride− 0.8\
− 1.4\
− 1.5^a^\
− 2.4^a^ Bailey et al. 2015 \[[@CR38]\]102274T2DPlacebo + Metformin\
Dapagliflozin 2.5 mg\
Dapagliflozin 5 mg\
Dapagliflozin 10 mg− 1.3\
− 0.6\
− 1.6\
− 3.9^a^ Nauck et al. 2011 \[[@CR93]\]52814T2DGlipizide + Metformin\
Dapagliflozin + Met+ 1.4\
− 3.2^a^ Nauck et al. 2014 \[[@CR94]\]104814T2DGlip + Metformin\
Dapagliflozin + Metformin+ 1.4\
− 3.7^a^ Del Prato et al. 2015 \[[@CR39]\]208814T2DGlipizide + Metformin\
Dapagliflozin (up to 20 mg) + Metformin+ 0.7\
− 4.4^a^SGLT2 inhibitors + GLP1-RA Fulcher et al. 2016 \[[@CR95]\]1895T2DPlacebo + GLP1-RA 300 mg\
Canagliflozin 100 mg + GLP1-RA 300 mg\
Canagliflozin 300 mg + GLP1-RA 300 mg− 0.6\
− 3.3^a^\
− 3.9^a^ Frias et al. 2016 \[[@CR17]\]28695T2DDapagliflozin 10 mg\
Exenatide 2 mg\
Dapagliflozin 10 mg + Exenatide 2 mg− 2.2\
− 1.6\
− 3.6^a^ Ludvik et al. 2018 \[[@CR96]\]24424T2DSGLT2 inhibitor + Placebo\
SGLT2 inhibitor + Dulaglutide 0.75 mg\
SGLT2 inhibitor + Dulaglutide 1.5 mg− 2.1\
− 2.6\
− 3.1^a^SGLT2 inhibitor ± DPP-4 inhibitor ± metformin Jabbour et al. 2014 \[[@CR97]\]24432T2DSitagliptin 100 mg + Placebo\
Sitagliptin 100 mg + Dapagliflozin 10 mg− 0.1\
− 1.9 Fulcher et al. 2016 \[[@CR95]\]18316T2DDPP-4 inhibitor + Placebo\
DPP-4 inhibitor + Canagliflozin 100 mg\
DPP-4 inhibitor + Canagliflozin 300 mg− 0.8\
− 2.7^a^\
− 3.5^a^ DeFronzo et al. 2015 \[[@CR98]\]52674T2DLinagliptin 5 mg\
Empagliflozin 25 mg + Linagliptin 5 mg\
Empagliflozin 10 mg + Linagliptin 5 mg\
Empagliflozin 25 mg\
Empagliflozin 10 mg− 0.3\
− 3.1^a^\
− 2.7\
− 2.8\
− 2.9 Pratley et al. 2018 \[[@CR99]\]521232T2DSitagliptin 100 mg\
Ertugliflozin 5 mg\
Ertugliflozin 15 mg\
Sitagliptin 100 mg + Ertugliflozin 5 mg\
Sitagliptin 100 mg + Ertugliflozin 15 mg− 0.1\
− 2.4\
− 3.2\
− 2.4\
− 2.8 Rosenstock et al. 2018 \[[@CR100]\]24534T2DSaxagliptin 5 mg + Placebo\
Dapagliflozin10 mg + Placebo\
Saxagliptin 5 mg + Dapagliflozin 10 mg0.0\
− 2.4\
− 2.1 Mathieu et al. 2016 \[[@CR101]\]52294T2DSaxagliptin 5 mg + Placebo\
Saxagliptin 5 mg + Dapagliflozin 10 mg− 0.4\
− 2.1SGLT2 inhibitor + thiazolidinediones Rosenstock et al. 2012 \[[@CR102]\]48420T2DPioglitazone\
Pioglitazone + Dapagliflozin 5 mg\
Pioglitazone + Dapagliflozin 10 mg+ 3.0\
+ 1.4\
+ 0.7 Kovacs et al. 2014 \[[@CR103]\]24498T2DPioglitazone\
Pioglitazone + Empagliflozin 10 mg\
Pioglitazone + Empagliflozin 25 mg+ 0.3\
− 1.6^a^\
− 1.5^a^SGLT2 inhibitor + insulin Wilding et al. 2014 \[[@CR104]\]104808T2DInsulin\
Insulin + Dapagliflozin 2.5 mg\
Insulin + Dapagliflozin 5 mg\
Insulin + Dapagliflozin 10 mg+ 1.8\
− 1.0^a^\
− 1.0^a^\
− 1.5^a^ Rosenstock et al. 2014 \[[@CR105]\]52563T2DInsulin + Placebo\
Insulin + Empagliflozin 10 mg\
Insulin + Empagliflozin 25 mg\
Insulin + Dapagliflozin 10 mg+ 0.4\
− 2.0^a^\
− 2.0^a^*T2D* type 2 diabetes; *SGLT2* sodium-glucose cotransporter 2; *DPP*-*4* dipeptidyl peptidase 4; *GLP1*-*RA* glucagon-like peptide 1 receptor agonist^a^Significantly different from placebo

Only a few studies have looked at the effects of SGLT2 inhibitors in weight loss in obese subjects without diabetes (Table [1](#Tab1){ref-type="table"}). Bays et al. have shown that canagliflozin 100 mg alone reduces body weight by 2.8 kg \[[@CR29]\]. Co-administration of SGLT2 inhibitors with GLP1-RA reduces body weight by 4.5 kg at 24 weeks of treatment, and this weight loss is maintained for up to 1 year (− 5.7 kg) in obese individuals without diabetes \[[@CR21], [@CR30]\]. Most importantly, the weight loss is mainly due to a reduction in subcutaneous and visceral adipose tissue, rather than lean tissue. Another study exploring the combination therapy of canagliflozin with phentermine, an amphetamine-like medication used to suppress appetite and approved for weight management, demonstrated superior weight loss compared with placebo (− 7.3 kg vs. − 0.6 kg) over a 26-week period \[[@CR42]\]. But studies exploring the effects of the combination therapy have been few and with limited doses. Therefore, the full potential for weight reduction needs to be explored in more studies including optimization of doses, safety, and inclusion of lifestyle intervention. There are currently other clinical trials evaluating the effects of SGLT2 inhibitors in obese individuals without diabetes used alone or in combination with other drugs (ClinicalTrial.gov identifier: NCT03093103, NCT03710460, NCT02635386, NCT02695810).

In diet-induced obese rats treated with SGLT2 inhibitors, lipolysis and circulating ketone body levels are increased \[[@CR43], [@CR44]\]. In patients with T2D or with obesity without diabetes, SGLT2 inhibitor-induced glycosuria lowers plasma glucose and insulin levels and raises fasting and post-meal glucagon concentrations. The reduction in the circulatory glucose concentration, together with the hormonal changes, results in mobilization of lipid storage \[[@CR24]\]. This leads to changes in energy substrate use, favoring the utilization of lipids for energy production \[[@CR45]\]. Under conditions of reduced portal insulin-to-glucagon ratio, lipolysis increases in adipose tissue and releases non-esterified fatty acids which are converted to ketone bodies in the liver through mitochondrial beta oxidation and ketogenesis \[[@CR25]\], resulting in a metabolic condition resembling a prolonged fast \[[@CR26]\].

Furthermore, SGLT2 inhibitors have been shown to reduce adipose tissue inflammation and to increase brown adipose tissue in rodent models \[[@CR46], [@CR47]\]. Reduction of inflammation in adipose tissue would be especially important in obesity, as low-grade chronic inflammation in adipose tissue is an important mediator in the development of obesity-related complications, such as insulin resistance and T2D \[[@CR48]\].

Cardiovascular Outcomes {#Sec5}
=======================

Cardiovascular outcomes trials with canagliflozin (Canagliflozin Cardiovascular Assessment Study; CANVAS), empagliflozin (Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; EMPA-REG OUTCOME), and dapagliflozin (The Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58; DECLARE-TIMI 58) suggest that SGLT2 inhibitors reduce the risk of fatal and nonfatal cardiovascular events and the relative risk of hospitalization for heart failure \[[@CR49]--[@CR51]\], which might indicate a class effect. Overall, results were similar between these trials; however, cardiovascular death was not significantly reduced in CANVAS, and major adverse cardiovascular effects were not reduced in DECLARE-TIMI58. Differences in the study population or trial design could account for these differences.

The possible mechanisms by which SGLT2 inhibitors reduce cardiovascular risk are unknown, but are likely to include reductions in hyperglycemia and body weight, osmotic diuresis, and reduced blood pressure \[[@CR52]--[@CR54]\].

Obese individuals are at increased risk of cardiovascular disease when compared with their non-obese counterparts (men: 1.46 \[1.20--1.77\]; women: 1.64 \[1.37--1.98\]) \[[@CR55]\]. Even though the effects of SGLT2 inhibitors on blood pressure and weight loss in obese individuals without T2D are identical to those reported in T2D subjects, it is unknown whether such effects can also translate into reduced cardiovascular disease events in this study population.

Reduction in Blood Pressure and Arterial Stiffness {#Sec6}
==================================================

High blood pressure is one of the most common co-morbidities associated with obesity \[[@CR55]\]. Weight loss will reverse many of the pathophysiological mechanisms of obesity-related hypertension. Therefore, it makes sense to aim at a therapy that induces weight loss and reduces hypertension along with a path that could also improve glucose metabolism. Even though SGLT2 inhibitors are not approved as antihypertensive agents, most trials with SGLT2 inhibitors have reported reductions in systolic and diastolic blood pressure of about 3--7 and 2 mmHg, respectively \[[@CR24], [@CR56]\]. Interestingly, the blood pressure reduction seems to be independent of disease status or presence of antihypertensive agents. The reason for the observed blood pressure reduction with SGLT2 inhibitors is not completely understood, but it is likely that several mechanisms including weight loss, diuretic effects, and reduction of the sympathetic activity are involved \[[@CR57]--[@CR59]\]. Furthermore, SGLT2 inhibitors have been shown to reduce arterial stiffness, thus also suggesting direct vascular effects. The significant decrease in blood pressure with SGLT2 inhibitors may provide a further advantage for obese patients when we take into account the high prevalence of hypertension among obese patients and the related cardiometabolic impact \[[@CR60]\].

Kidney Function {#Sec7}
===============

Emerging data suggest that SGLT2 inhibitors reduce the risk of progression of renal disease in T2D subjects, with a similar benefit in those with and without renal impairment \[[@CR27], [@CR61]\] and with and without atherosclerotic cardiovascular disease \[[@CR54]\]. Possible mechanisms of renal protection with SGLT2 inhibitors are multifactorial and it is likely that reduction in the glomerular capillary pressure, and reduction in an initial hyperfiltration, can contribute to the reduced albuminuria and prevention of renal impairment \[[@CR62], [@CR63]\]. However, these studies have limitations and were mainly conducted among populations with T2D and predominantly normal to middle baseline kidney function. Other long-term trials designed to evaluate whether SGLT2 inhibitors have renal protective effects in participants with T2D, and without T2D but with or without chronic kidney disease and macroalbuminuria are ongoing (e.g., the "Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) study," NCT02065791; and the "EMPAagliflozin and RAs in Kidney Disease (EMPRA)," NCT03078101). In obese subjects without diabetes, SGLT2 inhibitors do not alter the estimated glomerular filtration rate or have any adverse event potentially related to renal impairment or renal failure over a 52-week period \[[@CR21]\].

Blood Lipids {#Sec8}
============

Generally, there are minor effects on lipid profile with SGLT2 inhibitor treatment. Even though some studies have shown that SGLT2 inhibitors modestly increase HDL cholesterol levels compared with placebo, there are also available data suggesting a small increase in LDL cholesterol \[[@CR26], [@CR29]\]. Therefore, there is currently no clear evidence that changes in blood lipoproteins are of importance for the overall clinical outcomes following SGLT2 inhibitor treatment.

SGLT2 Inhibitors in Type 1 Diabetes (T1D) {#Sec9}
=========================================

SGLT2 inhibitors may also be of benefit in T1D, in addition to insulin, although they have not yet been approved for this indication. A few trials have assessed the efficacy and safety of SGLT2 inhibitors in T1D. SGLT2 inhibitors (dapagliflozin and empagliflozin) reduce HbA1c (about 2--4 mmol/L), body weight (1--2 kg), and the total required insulin dose compared to placebo \[[@CR64], [@CR65]\]. In another trial, sotagliflozin, which can inhibit both SGLT2 and SGLT1, added to insulin significantly lowered HbA1c, systolic blood pressure, and body weight, and required significantly less daily insulin compared to placebo \[[@CR66]\]. One of the main concerns for any glucose-lowering drug in T1D is the risk of hypoglycemia. Notably, no increase in the hypoglycemic events is reported with SGLT2 inhibitors or sotagliflozin, compared to a placebo group in T1D subjects. However, a higher risk of diabetic ketoacidosis is observed with SGLT2 inhibitors. Therefore, more studies are needed with SGLT2 inhibitors in T1D patients, to fully evaluate their therapeutic potential in this specific population.

Safety and Tolerability {#Sec10}
=======================

One advantage of SGLT2 inhibitors, compared with several other glucose-lowering therapies, is the low potential to induce hypoglycemia, unless combined with insulin or insulin secretagogues \[[@CR25]\]. This is because urinary glucose excretion by default falls or ceases when plasma glucose drops, but there can also be contributions through sympathetic nervous activation during hypoglycemia that reduces the glomerular filtration rate and hence glucosuria \[[@CR67]\], as well as through increased hepatic gluconeogenesis \[[@CR68]\].

In general, SGLT2 inhibitors are well tolerated and the most common adverse effect is an increased risk of mycotic genital infections by about four- to sixfold versus placebo or active comparator, and this is seen in both women and men \[[@CR26], [@CR32]\]. This is a result of increased glucose concentration in the urine that can facilitate the onset of infections in the lower urogenital regions. The same mechanism is also expected to promote infections of the urinary tract, but in meta-analyses there is a trend for a minor increase up to 1.5-fold, and this is not consistent among studies \[[@CR25]--[@CR27]\]. The risks for such side effects are similar among different SGLT2 inhibitors.

Recent evidence suggests that episodes of ketoacidosis can also occur \[[@CR69]\], and it might be of particular concern among insulin-deficient individuals, including those with longstanding T2D, T1D, or latent autoimmune diabetes in adults (LADA) \[[@CR70]\].

Finally, the CANVAS program has reported an increased risk of bone fractures and lower-limb amputations with canagliflozin \[[@CR49]\]. Neither bone fracture nor lower-limb amputation has been reported with the other SGLT2 inhibitors, or in another real-world analysis study \[[@CR71]\], so additional evaluation is needed before drawing definite conclusions.

Future Perspectives {#Sec11}
===================

Monotherapy {#Sec12}
-----------

Given the modest weight loss delivered by SGLT2 inhibitors, it is not likely that they will be successful as monotherapies for obesity. It could be argued that doses higher than those used to treat hyperglycemia may be more effective. However, as the glucosuric effect is self-limiting when plasma glucose is lowered, it is not expected to markedly increase efficacy. Accordingly, weight loss is not clearly improved in studies with a high degree of SGLT2 inhibition (like canagliflozin 300 mg) compared to partial inhibition, for example with empagliflozin 10 mg. The expected weight loss due to loss of up to 400 kcal energy into the urine may be as much as 11 kg \[[@CR40]\], but a compensatory increase of food intake probably accounts for the partial off-set of weight loss. Nonetheless, certain obese individuals at very high risk of T2D, atherosclerotic cardiovascular disease, heart failure, or renal failure could benefit from such a monotherapy. That will, however, require compelling results from targeted clinical trials. There are ongoing studies in patients with heart and renal failure, respectively (NCT03057951; NCT03078101; NCT03057977; NCT03594110; NCT03036124 \[[@CR63]\]). Those studies include patients both with and without diabetes as well as obesity.

Combination Therapy {#Sec13}
-------------------

In contrast to monotherapy, an SGLT2 inhibitor in combination with a drug that reduces food intake is appealing as a means to mitigate the physiologic mechanisms that counteract weight loss (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR72]\]. Such combination pharmacotherapy may achieve greater reduction of body weight in two ways. First, the increased food intake evoked by energy loss during SGLT2 inhibition could partly be prevented by an appetite-reducing therapy. Second, the reduced cellular energy expenditure occurring after weight loss achieved by an appetite-reducing drug may be balanced by the urinary caloric loss secondary to glucosuria \[[@CR41]\]. Therefore, the complementary mechanisms of action of an SGLT2 inhibitor and a GLP1-RA (through its effect to reduce appetite and possibly also its ability to slow gastric emptying) may provide an attractive approach for obesity treatment (Fig. [1](#Fig1){ref-type="fig"}). Our recent study addressing this treatment concept showed modest weight-loss effects \[[@CR30], [@CR31]\], but further studies with optimized doses are encouraged. Also, the trajectories of bodyweight change during SGLT2 inhibitor treatment varies substantially between individuals. Precision medicine approaches may also provide an opportunity to select patients who are receptive to the greater efficacy of this combination therapy. In our previous work on combination treatment with an SGLT2 inhibitor and GLP1-RA, we found some baseline characteristics that might identify responders, and relatively low BMI and low insulin secretion were associated with greater bodyweight loss \[[@CR73]\]. In addition, the occurrence of the A allele of the SNP10010131, which is related to GLP-1-induced insulin secretion \[[@CR74]\], was found to be associated with relatively greater bodyweight loss \[[@CR73]\]. One study has found an association between a genetic variation in the SGLT2 gene (the rs9934336 G-allele) and increased plasma glucose and insulin concentrations during an oral glucose tolerance test \[[@CR75]\]. However, no common genetic variants in the SGLT2 gene, or other genes, have shown a clinically relevant impact on treatment responses to SGLT2 inhibitors \[[@CR76]\]. Further studies to characterize the good and poor responders are encouraged in the future.Fig. 1Effects of SGLT2 inhibition in combination with a drug that reduces food intake (e.g., GLP1-RA) on energy intake and energy expenditure and compensatory effects

Among patients with T2D \[[@CR40]\], estimated caloric intake is increased by an average of 10--15% during chronic treatment with an SGLT2 inhibitor; this offsets about 9 kg of an expected glucosuria-induced bodyweight loss of 11 kg over 2 years \[[@CR77]\]. From the magnitude of bodyweight loss observed in the current study, it might be inferred that food intake was reduced by the addition of exenatide, thus counteracting the dapagliflozin-induced increase in food intake.

Further support for the combination of an SGLT2 inhibitor with agents that reduce appetite (and/or increase satiety) is provided by a clinical trial of canagliflozin and phentermine, given either in combination or each drug alone. In this study, there was about a 7% placebo-adjusted reduction in bodyweight with the combination and about 2% and 4% with canagliflozin or phentermine alone, respectively \[[@CR42]\].

It would be of interest to further explore combination therapies involving an SGLT2 inhibitor together with an agent that reduces food intake. Such agents include novel more efficacious GLP1-RAs such as semaglutide (which is also being developed in an oral formulation) or so-called dual peptides like GLP1 + GIP \[[@CR78]\] or GLP1 + glucagon \[[@CR79]\]. The most recently approved anti-obesity medicines, lorcaserin, topiramate + phentermine, and bupropion + naltrexone, respectively, work mainly via appetite reduction \[[@CR80]\]. They could also very well become more effective if administered in combination with an SGLT2 inhibitor.

SGLT2 inhibitors increase glucagon secretion according to some reports, and this might reduce the glucose-lowering effect \[[@CR34]\]. However, co-administration with GLP1-RA may counteract this effect \[[@CR73]\]. The prevention of the glucagon rise might improve the beneficial effects of the combination therapy to enhance glucose control and may support this combination therapy in clinical practice \[[@CR81]\].

As far as we are aware, ongoing clinical trials are mainly looking at the effects of SGLT2 inhibitors in obese subjects without diabetes as a monotherapy (NCT03710460; NCT01756404; NCT02833415), and one study is evaluating the combination of dapagliflozin and exenatide in overweight/obese non-diabetic women with PCOS (NCT02635386). In particular, the combination of an SGLT2 inhibitor with one of the novel appetite-reducing agents showing marked bodyweight loss (up to about 10 kg), e.g., the LY3298176 GLP1 + GIP-RA \[[@CR78]\] or injected semaglutide, would be attractive. The addition of SGLT2 inhibitors could probably improve both short-term weight loss and long-term weight maintenance.

Conclusion {#Sec14}
==========

Several studies support the concept that SGLT2 inhibitors can be effective as adjuvant weight loss therapy when given together with agents that reduce food intake, and such combination treatments appear attractive. In contrast, SGLT2 inhibitor monotherapy is not likely to provide sufficient weight loss for treatment of obesity per se, but could have other benefits in obese patients with co-morbidities such as atherosclerotic cardiovascular disease, heart failure, or renal disease. Moreover, further research is warranted to address phenotypic and genotypic characteristics that may help to identify treatment responders to weight-loss therapies that include SGLT2 inhibitors.
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